Comparison · NCT00600340-sae
Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bevacizumab Plus Paclitaxel vs Bevacizumab Plus Capecitabine: serious adverse events. Trial comparisons, record NCT00600340-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00600340-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.229 | 0.184 | 0.281 | wilson | |
| Risk in group 2 | 0.245 | 0.199 | 0.299 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0166 | -0.0869 | 0.0537 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.932 | 0.693 | 1.25 | log | |
| Odds ratio, group 1 over group 2 | 0.912 | 0.618 | 1.35 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bevacizumab Plus Paclitaxel than on Bevacizumab Plus Capecitabine | 60.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bevacizumab Plus Paclitaxel | Bevacizumab 10 mg/kg intravenous (i.v.), days 1 and 15, every 4 weeks, Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks | 65 | 284 | EG000 |
| Group 2 | Bevacizumab Plus Capecitabine | Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks, Capecitabine 1000 mg/m² twice-daily, days 1-14, every 3 weeks | 68 | 277 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From start of study drug administration until 28 days after the last dose of study medication, assessed up to approximately 5 years
Source ClinicalTrials.gov
Trial
- Title
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- NCT number
- NCT00600340
- Phases
- PHASE3
- Conditions
- Metastatic Breast Cancer
- Interventions
- Bevacizumab and Paclitaxel, Bevacizumab and Capecitabine
- Lead sponsor
- Central European Cooperative Oncology Group
- Results first posted
- 2019-12-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00600340?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00600340-sae